Related content

Recognition of naturally processed and ovarian cancer reactive CD8⁺ T cell epitopes within a promiscuous HLA class II T-helper region of NY-ESO-1

By Matsuzaki Junko   Qian Feng   Luescher Immanuel   Lele Shashikant   Ritter Gerd   Shrikant Protul   Gnjatic Sacha   Old Lloyd   Odunsi Kunle  

Cancer Immunology, Immunotherapy, Vol. 57, Iss. 8, 2008-08 ,pp. : 1185-1195

Springer Publishing Company

Access to resources Recommend Favorite

Introduction: MHC class II-restricted antigen presentation

By Miller J.   Sant A.J.  

Seminars in Immunology, Vol. 7, Iss. 6, 1995-12 ,pp. : 343-346

Academic Press

Access to resources Recommend Favorite

MHC class II and CD80 tumor cell–based vaccines are potent activators of type 1 CD4⁺ T lymphocytes provided they do not coexpress invariant chain

By Ilkovitch Dan   Ostrand-Rosenberg Suzanne  

Cancer Immunology, Immunotherapy, Vol. 53, Iss. 6, 2004-06 ,pp. : 525-532

Springer Publishing Company

Access to resources Recommend Favorite

Identification of a MHC class-II restricted epitope in carcinoembryonic antigen

By Shen Lei   Schroers Roland   Hammer Juergen   Huang Xue   Chen Si-Yi  

Cancer Immunology, Immunotherapy, Vol. 53, Iss. 5, 2004-05 ,pp. : 391-403

Springer Publishing Company

Access to resources Recommend Favorite

Fc receptors for IgG and antigen presentation on MHC class I and class II molecules

By Amigorena S.   Bonnerot C.  

Seminars in Immunology, Vol. 11, Iss. 6, 1999-12 ,pp. : 385-390

Academic Press

Access to resources Recommend Favorite